Linked Data API

Show Search Form

Search Results

1136781
star this property registered interest false more like this
star this property date less than 2019-07-03more like thismore than 2019-07-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Academic Health Science Networks more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government by what process, during the current development of policy options for Academic Health Science Centres (AHSC), potential new AHSCs can be considered in areas of England currently unrepresented by existing AHSCs. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL16931 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-17more like thismore than 2019-07-17
star this property answer text <p>The Department-designated Academic Health Science Centres (AHSCs) along with the Academic Health Science Networks (AHSNs) and the National Institute for Health Research (NIHR) Applied Research Collaborations (ARCs) are all important components of the country’s health research and innovation ecosystem.</p><p>The six current Department-designated AHSCs were made on the basis of an open competition, which was open to eligible National Health Service and University partnerships across England. The recommendations for designation were made to the Department by an international independent panel.</p><p>The remit of the Accelerated Access Collaborative (AAC) has recently been expanded to become the umbrella body across the United Kingdom health innovation eco-system. The AAC has been asked to consider the role of new AHSCs within the health system and to ensure that they complement the innovation landscape, rather than add further complexity to it.</p><p>It is not possible to provide specific details of the scope and nature of the new designation process at this stage given that the AAC is currently actively considering this. However, it is expected that the future designation process would be open to all NHS and University partnerships across England which meet the published specification to apply, including partnerships in areas of England where there is currently no Departmental-AHSC. As with the previous AHSC designation process, any future process will be run via a full and open competition, assessed by an independent expert panel. Rigorous conflict of interest policies will also be in place throughout the process for all involved to ensure any potential conflicts are dealt with appropriately.</p><p>The existing Departmental-AHSC designation will be extended until the end of March 2020 to enable a new designation process to be undertaken. The Department’s expectation is that AHSCs will play an increasingly important role in the health innovation and research landscape over the coming years.</p><p>As currently, the success of any newly designated AHSCs will require close interplay and cooperation between research infrastructure, including NIHR Biomedical Research Centres (BRCs) and the NIHR ARCs, and with the AHSNs and wider innovation landscape.</p><p>As part of annual monitoring of the existing Department-designated AHSCs, examples of innovations arising from them have been reported to have been made available to patients in the NHS. These include:</p><p>- The King’s Health Partners Heart Failure Service, which brings together clinical, research and educational expertise to deliver world class heart care in south London, helping people with heart failure live longer and with better quality of life;</p><p>- University College London Partners AHSC adoption of a Learning Health System to standardise data entry and allowing the widespread trialling of novel tools to detect atrial fibrillation early;</p><p>- The Manchester AHSC working with partners to align research around core health and social care priorities; and supporting the roll out of a single blood test driven decision-aid for patients presenting with chest pain at local emergency departments; and</p><p>- The roll out of the innovative Sleepio app by the Oxford AHSN to support those suffering from insomnia across Oxfordshire, Berkshire and Buckinghamshire.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16932 more like this
HL16934 more like this
star this property question first answered
less than 2019-07-17T16:29:08.16Zmore like thismore than 2019-07-17T16:29:08.16Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this
1141958
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Pertuzumab more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what advice they provide to clinicians for the use of Pertuzumab rather than Herceptin for the treatment of HER2+ breast cancer. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL17502 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL17501 more like this
star this property question first answered
less than 2019-07-25T16:45:03.207Zmore like thismore than 2019-07-25T16:45:03.207Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this
1141957
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Breast Cancer: Drugs more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what are the drugs approved by NICE to treat HER2+ breast cancer; and what assessment they have made of the efficacy of such drugs. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL17501 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL17502 more like this
star this property question first answered
less than 2019-07-25T16:45:03.16Zmore like thismore than 2019-07-25T16:45:03.16Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this
1136784
star this property registered interest false more like this
star this property date less than 2019-07-03more like thismore than 2019-07-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Academic Health Science Networks more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of whether the innovations arising from the current phase of Academic Health Science Centres are being made available to patients throughout the NHS. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL16934 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-17more like thismore than 2019-07-17
star this property answer text <p>The Department-designated Academic Health Science Centres (AHSCs) along with the Academic Health Science Networks (AHSNs) and the National Institute for Health Research (NIHR) Applied Research Collaborations (ARCs) are all important components of the country’s health research and innovation ecosystem.</p><p>The six current Department-designated AHSCs were made on the basis of an open competition, which was open to eligible National Health Service and University partnerships across England. The recommendations for designation were made to the Department by an international independent panel.</p><p>The remit of the Accelerated Access Collaborative (AAC) has recently been expanded to become the umbrella body across the United Kingdom health innovation eco-system. The AAC has been asked to consider the role of new AHSCs within the health system and to ensure that they complement the innovation landscape, rather than add further complexity to it.</p><p>It is not possible to provide specific details of the scope and nature of the new designation process at this stage given that the AAC is currently actively considering this. However, it is expected that the future designation process would be open to all NHS and University partnerships across England which meet the published specification to apply, including partnerships in areas of England where there is currently no Departmental-AHSC. As with the previous AHSC designation process, any future process will be run via a full and open competition, assessed by an independent expert panel. Rigorous conflict of interest policies will also be in place throughout the process for all involved to ensure any potential conflicts are dealt with appropriately.</p><p>The existing Departmental-AHSC designation will be extended until the end of March 2020 to enable a new designation process to be undertaken. The Department’s expectation is that AHSCs will play an increasingly important role in the health innovation and research landscape over the coming years.</p><p>As currently, the success of any newly designated AHSCs will require close interplay and cooperation between research infrastructure, including NIHR Biomedical Research Centres (BRCs) and the NIHR ARCs, and with the AHSNs and wider innovation landscape.</p><p>As part of annual monitoring of the existing Department-designated AHSCs, examples of innovations arising from them have been reported to have been made available to patients in the NHS. These include:</p><p>- The King’s Health Partners Heart Failure Service, which brings together clinical, research and educational expertise to deliver world class heart care in south London, helping people with heart failure live longer and with better quality of life;</p><p>- University College London Partners AHSC adoption of a Learning Health System to standardise data entry and allowing the widespread trialling of novel tools to detect atrial fibrillation early;</p><p>- The Manchester AHSC working with partners to align research around core health and social care priorities; and supporting the roll out of a single blood test driven decision-aid for patients presenting with chest pain at local emergency departments; and</p><p>- The roll out of the innovative Sleepio app by the Oxford AHSN to support those suffering from insomnia across Oxfordshire, Berkshire and Buckinghamshire.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16931 more like this
HL16932 more like this
star this property question first answered
less than 2019-07-17T16:29:08.27Zmore like thismore than 2019-07-17T16:29:08.27Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this
1136783
star this property registered interest false more like this
star this property date less than 2019-07-03more like thismore than 2019-07-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Medicine: Research more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what governance arrangements they have proposed for the newly designated Academic Research Collaborations. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL16933 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-15more like thismore than 2019-07-15
star this property answer text <p>Following, a new, open competition, the Government has recently announced National Institute of Health Research (NIHR) designation and funding for 15 Applied Research Collaborations (ARCs), with total funding of £135 million over five years from 1 October 2019.</p><p>Each NIHR ARC will have its own local governance arrangements in place, with the named Director of each NIHR ARC having responsibility, and authority over, the NIHR funding awarded to their National Health Service organisations through the scheme. Under the terms of the NIHR contract, the NIHR ARCs will be required to submit annual progress reports and can be subject site visits to evaluate progress, performance and identify key issues.</p><p>All NIHR ARCs are required to ensure that research is conducted in accordance with the United Kingdom Policy Framework for Health and Social Care Research and the Concordat to Support Research Integrity and the Governance Arrangements for Research Ethics Committees.</p><p> </p><p> </p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-07-15T10:25:42.427Zmore like thismore than 2019-07-15T10:25:42.427Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this
1136782
star this property registered interest false more like this
star this property date less than 2019-07-03more like thismore than 2019-07-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Medicine: Research more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what the future relationship will be between Academic Health Science Networks, Academic Health Science Centres and Academic Research Collaborations with regard to the future applied health science ecosystem. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL16932 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-07-17more like thismore than 2019-07-17
star this property answer text <p>The Department-designated Academic Health Science Centres (AHSCs) along with the Academic Health Science Networks (AHSNs) and the National Institute for Health Research (NIHR) Applied Research Collaborations (ARCs) are all important components of the country’s health research and innovation ecosystem.</p><p>The six current Department-designated AHSCs were made on the basis of an open competition, which was open to eligible National Health Service and University partnerships across England. The recommendations for designation were made to the Department by an international independent panel.</p><p>The remit of the Accelerated Access Collaborative (AAC) has recently been expanded to become the umbrella body across the United Kingdom health innovation eco-system. The AAC has been asked to consider the role of new AHSCs within the health system and to ensure that they complement the innovation landscape, rather than add further complexity to it.</p><p>It is not possible to provide specific details of the scope and nature of the new designation process at this stage given that the AAC is currently actively considering this. However, it is expected that the future designation process would be open to all NHS and University partnerships across England which meet the published specification to apply, including partnerships in areas of England where there is currently no Departmental-AHSC. As with the previous AHSC designation process, any future process will be run via a full and open competition, assessed by an independent expert panel. Rigorous conflict of interest policies will also be in place throughout the process for all involved to ensure any potential conflicts are dealt with appropriately.</p><p>The existing Departmental-AHSC designation will be extended until the end of March 2020 to enable a new designation process to be undertaken. The Department’s expectation is that AHSCs will play an increasingly important role in the health innovation and research landscape over the coming years.</p><p>As currently, the success of any newly designated AHSCs will require close interplay and cooperation between research infrastructure, including NIHR Biomedical Research Centres (BRCs) and the NIHR ARCs, and with the AHSNs and wider innovation landscape.</p><p>As part of annual monitoring of the existing Department-designated AHSCs, examples of innovations arising from them have been reported to have been made available to patients in the NHS. These include:</p><p>- The King’s Health Partners Heart Failure Service, which brings together clinical, research and educational expertise to deliver world class heart care in south London, helping people with heart failure live longer and with better quality of life;</p><p>- University College London Partners AHSC adoption of a Learning Health System to standardise data entry and allowing the widespread trialling of novel tools to detect atrial fibrillation early;</p><p>- The Manchester AHSC working with partners to align research around core health and social care priorities; and supporting the roll out of a single blood test driven decision-aid for patients presenting with chest pain at local emergency departments; and</p><p>- The roll out of the innovative Sleepio app by the Oxford AHSN to support those suffering from insomnia across Oxfordshire, Berkshire and Buckinghamshire.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN
HL16931 more like this
HL16934 more like this
star this property question first answered
less than 2019-07-17T16:29:08.223Zmore like thismore than 2019-07-17T16:29:08.223Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this
1141959
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Breast Cancer: Clinical Trials more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government which clinical trials are currently recruiting patients with HER2+ breast cancer. more like this
star this property tabling member printed
Lord Willis of Knaresborough remove filter
star this property uin HL17503 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-08-07more like thismore than 2019-08-07
star this property answer text <p>The Department’s National Institute for Health Research (NIHR) is currently recruiting to 15 clinical trials for people with HER2+ breast cancer via its Clinical Research Network. The majority of these are commercially funded. To date, a total of 7,986 participants have been recruited to these 15 trials.</p><p>Of the 15 clinical trials, 12 are commercially sensitive, with appropriate cost recovery from the companies. The data for these commercial trials has been provided from the relevant companies as ‘commercial in confidence’ hence we are unable to provide details about these trials such as their titles.</p><p>However, the three clinical trials which are not commercially sensitive are:</p><p>- Cancer Research UK; NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC). Title: The UK plasma based Molecular profiling of Advanced breast cancer to inform Therapeutic Choices (plasmaMATCH);</p><p>- Cancer Research UK. Title: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer; and</p><p>- Medical Research Council. Title: A mechanistic non-invasive imaging study of HER2 expression in breast cancer using [18F]GE-226 positron emission tomography.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-08-07T11:43:14.327Zmore like thismore than 2019-08-07T11:43:14.327Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4151
star this property label Biography information for Lord Willis of Knaresborough more like this